The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

Clinical Therapeutics

Volumn 18, Issue 5, 1996, Pages 797-810

  Oparil, Suzanne ^a   Dyke, Stephen ^b   Harris, Freeman ^c   Kief, Jan ^d   James, Deborah ^e   Hester, Allen ^e   Fitzsimmons, Sheila ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b New England Clinical Research Center   (United States)

^c Oakridge Medical Clinic   (United States)

^d Western States Clinical Research   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALSARTAN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL LABORATORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REBOUND; SITTING; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0029969837     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80040-3     Document Type: Article

References (21)

1. Burt V, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the U.S. adult population. Hypertension. 1995;25: 305-313.
2. Oparil S. Antihypertensive therapy in the era of evidence based medical practice: What to do until the facts are in. Curr Opin Nephrol Hypertens. 1996;5:159-161. Editorial commentary.
3. Setaro JF, Black JR. Refractory hypertension. NEJM. 1992;327:543-547.
4. Sackett DL, Haynes RB, Gibson ES, et al. Randomized clinical trial of strategies for improving medication compliance in primary hypertension. Lancet. 1975;1: 1205-1207.
5. Haynes RB, Mattson ME, Chobanian AV, et al. Management of patient compliance in the treatment of hypertension: Report of the NHLBI working group. Hypertension. 1982;4:415-423.
6. Johnston CI. Angiotensin receptor antagonists: Focus on losartan. Lancet. 1995; 346:1403-1407.
7. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists: A new class of antihypertensive drugs. Arch Intern Med. 1995;155:1361-1368.
8. Fletcher AE, Palmer AJ, Bulpitt CJ. Cough with angiotensin converting enzyme inhibitors: How much of a problem? J Hypertens Suppl. 1994;12:S43-S47.
9. Morice AH, Brown MJ, Higenbottom T. Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol. 1989;13(Suppl):S59-S62.
10. 1 receptor subtype. Br J Pharmacol. 1993; 110:761-771.
11. Müller P, Cohen T, de Gasparo M, et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol. 1994;47:231-245.
12. Data on file, Ciba-Geigy Corporation, Summit, New Jersey, 1995.
13. Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. Guidelines for the management of mild hypertension: Memorandum from WHO/ISH meeting. Clin Exp Hypertens. 1993;15:1363-1395.
14. Frishman WH, Goldberger J, Sherman D. Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension. J Clin Hypertens. 1987;3: 520-527.
15. Tikkanen I, Omvik P, Jensen HÆ, for the Scandinavian Study Group. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 1995;13: 1343-1351.
16. Boissel J-P, Collet J-P, Lion L, et al. A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients; field trial in general practice. J Hypertens. 1995;13:1059-1067.
17. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996;60:341-346.
18. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. Efficacy and safety compared to placebo and enalapril. J Hypertens. 1996; 14:1147-1151.
19. Hegner G, Faust G, Freytag F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide. Eur J Pharmacol. In press.
20. Kaplan NM, Lieberman E. Clinical Hypertension. Baltimore, Md: Williams & Wilkins; 1986.
21. Houston MC. Abrupt cessation of treatment in hypertension: Consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J. 1981;102:415-430.